Within 3 days on Neocate LCP, studies showed significant improvement of eczema and disappearance of other symptoms (e.g. vomiting, diarrhoea)2.
Within 14 days on Neocate LCP, studies showed resolution of all gastrointestinal symptoms. 100% of infants gained weight whilst receiving the AAF3.
Neocate LCP is the only AAF with over 35 years clinical experience and is the most researched formula in the UK market1.
More publications (>95) support the use of Neocate LCP than any other hypoallergenic amino acid-based product1.
Up to 10% of infants with uncomplicated CMA and up to 40% of infants with more complex allergy may not tolerate an EHF.4 Guidelines suggest that symptoms should resolve within 2-4 weeks on an EHF in most infants, however, where symptoms persist on an EHF, or in formula fed infants with severe CMA, an AAF should be considered.5
For a detailed nutritional breakdown, please view the data card.
Neocate LCP does not contain the live beneficial bacteria Bifidobacterium breve M-16V. This means Neocate LCP can be used in patients where an AAF containing live bacteria would be contraindicated.
Neocate Syneo is the only† amino acid-based formula to contain a synbiotic blend of both prebiotics and probiotics*.
† Product can be provided to patients upon the request of a Healthcare Professional. They are intended for the purpose of professional evaluation only.
Please ensure your role and areas of interest are up to date.